The results of FOCUS4-C, where patients whose tumours were both RAS-mutant and TP53-mutant, were randomised between adavosertib and active monitoring, showed that adavosertib improved progression free survival), and importantly for the patients, was well tolerated.6 The gene discussed is TP53; the disease is neoplasm.